Table 3.
Comparison between acute and follow-up CMR scans of myocarditis patients after COVID-19 vaccination.
|
Acute myocarditis after COVID-19 vaccination (n = 16) |
Follow-up myocarditis after COVID-19 vaccination (n = 14) |
Acute vs. follow-up CMR, myocarditis after COVID-19 vaccination (P values) |
|
|---|---|---|---|
| Elapsed time, days | 4 ± 2 | 112 ± 27 | NA |
| LVEF, % | 58 ± 6 | 60 ± 3 | 0.042 |
| LVEDVi, ml/m2 | 87 ±13 | 83 ± 9 | 0.046 |
| LVSVi, ml/m2 | 50 ± 7 | 50 ± 6 | 0.961 |
| LVMi, g | 53 ± 10 | 51 ± 7 | 0.228 |
| GLS, % | −20.5 [−22.5, −19] | −21 [−22, −20] | 0.083 |
| RVEF, % | 58 ± 4 | 57 ± 5 | 0.559 |
| RVEDVi, ml/m2 | 83 ± 10 | 84 ± 9 | 0.722 |
| RVSVi, ml/m2 | 48 ± 6 | 48 ± 6 | 0.489 |
| T1 mapping septal, ms | 966 [951, 1,016] | 957 [950, 965] | 0.578 |
| T1 mapping affected area, ms | 1,056 [1,038, 1,113] | 976 [953.5, 1,018] | 0.031 |
| T2 mapping septal, ms | 43 [43, 44] | 43 [42, 43] | 0.375 |
| T2 mapping affected area, ms | 51 [50, 55] | 44 [43, 47.5] | 0.016 |
| ECV septal, % | 26 [24, 28] | 25.5 [23.5, 27.5] | 0.125 |
| ECV affected area,% | 38 [35, 41.5] | 30.5 [28, 35] | 0.016 |
| LGE g | 6 [3, 10] | 2 [0.5, 4] | 0.001 |
| LGE % | 7 [3, 12] | 3 [1, 4] | 0.001 |
Comparison between acute and follow-up CMR scans myocarditis after COVID-19 immunization. Continuous variables showing a normal distribution are presented as the mean and standard deviations (± SD), and those showing a non-normal distribution are reported as medians and interquartile ranges [IQRs]. Acute and follow-up examinations were compared using paired sample t tests and Wilcoxon tests.
CMR, cardiac magnetic resonance; ECV, extracellular volume; EDVi, left ventricular end diastolic volume index; EF, ejection fraction; ESVi, end systolic volume index; GLS, global longitudinal strain; Mi, mass index; NA, not applicable; LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular; SVi, left ventricular stroke volume index.